331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function
OBJECTIVES/GOALS: Determine the exosome mitochondrial DNA (mtDNA) copy number in cerebrospinal fluid (CSF) as a measure of neuronal mitochondrial integrity in patients with subarachnoid hemorrhage (SAH). Determine the patterns of beta amyloid and tau protein biology in CSF of SAH patients and correl...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2024-04-01
|
| Series: | Journal of Clinical and Translational Science |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866124002978/type/journal_article |
| _version_ | 1797226925909868544 |
|---|---|
| author | Dhanushki Abeykoon Xiaowan Wang Lesya Novikova Amol Ranjan Alexander Gabrielli Russell Swerdlow |
| author_facet | Dhanushki Abeykoon Xiaowan Wang Lesya Novikova Amol Ranjan Alexander Gabrielli Russell Swerdlow |
| author_sort | Dhanushki Abeykoon |
| collection | DOAJ |
| description | OBJECTIVES/GOALS: Determine the exosome mitochondrial DNA (mtDNA) copy number in cerebrospinal fluid (CSF) as a measure of neuronal mitochondrial integrity in patients with subarachnoid hemorrhage (SAH). Determine the patterns of beta amyloid and tau protein biology in CSF of SAH patients and correlate those measures with the clinical status of the SAH patients. METHODS/STUDY POPULATION: The CSF is collected from SAH patients undergoing ventriculostomy-based continuous CSF drainage. Adults from all ethnicities and sex are included in this study. The exosomes are isolated from CSF samples using a precipitation method and particle count and size are measured using NanoSight. The DNA is extracted using an exosomal DNA isolation kit (XCF kit). The CSF mtDNA copy number is measured using digital drop PCR with mitochondrial DNA primers. The levels of beta-amyloid (a-beta-40 and -42) and tau protein in CSF are measured using a sensitive ELISA-based assay. A quantitative evaluation of mitochondrial DNA copy number, clinical status of the SAH patients and beta amyloid, and tau protein levels will be conducted and reported. RESULTS/ANTICIPATED RESULTS: Preliminary results of four CSF samples showed similar patterns in CSF exosome particle number, particle size and exosomal mtDNA copy number in relation to samples from the admission day. Particle number decreased with time while particle size increased. More patient samples will be analyzed to confirm the patterns. We anticipate that mtDNA copy number will correlate with brain beta-amyloid and tau protein levels. Moreover, we anticipate that the clinical status of the SAH patients will associate with the mtDNA copy number. We specifically predict that higher mtDNA copy number levels will correlate with better clinical outcomes. DISCUSSION/SIGNIFICANCE: Mitochondrial function is critical to brain health, but we lack effective ways to monitor this parameter. Here we focus on a CSF based biomarker, exosome-derived mtDNA, which is intended to reflect the integrity of brain mitochondria. As bioenergetic metabolism influences beta amyloid and tau biology, predicting those levels are important. |
| first_indexed | 2024-04-24T14:32:39Z |
| format | Article |
| id | doaj.art-fd549141ead5466a84d4fbb0446fef44 |
| institution | Directory Open Access Journal |
| issn | 2059-8661 |
| language | English |
| last_indexed | 2024-04-24T14:32:39Z |
| publishDate | 2024-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Clinical and Translational Science |
| spelling | doaj.art-fd549141ead5466a84d4fbb0446fef442024-04-03T02:00:21ZengCambridge University PressJournal of Clinical and Translational Science2059-86612024-04-01810110110.1017/cts.2024.297331 Validation of a Novel CSF-Based Biomarker of Mitochondrial FunctionDhanushki Abeykoon0Xiaowan Wang1Lesya Novikova2Amol Ranjan3Alexander Gabrielli4Russell Swerdlow5University of Kansas Medical CenterUniversity of Kansas Medical CenterUniversity of Kansas Medical CenterUniversity of Kansas Medical CenterUniversity of Kansas Medical CenterUniversity of Kansas Medical CenterOBJECTIVES/GOALS: Determine the exosome mitochondrial DNA (mtDNA) copy number in cerebrospinal fluid (CSF) as a measure of neuronal mitochondrial integrity in patients with subarachnoid hemorrhage (SAH). Determine the patterns of beta amyloid and tau protein biology in CSF of SAH patients and correlate those measures with the clinical status of the SAH patients. METHODS/STUDY POPULATION: The CSF is collected from SAH patients undergoing ventriculostomy-based continuous CSF drainage. Adults from all ethnicities and sex are included in this study. The exosomes are isolated from CSF samples using a precipitation method and particle count and size are measured using NanoSight. The DNA is extracted using an exosomal DNA isolation kit (XCF kit). The CSF mtDNA copy number is measured using digital drop PCR with mitochondrial DNA primers. The levels of beta-amyloid (a-beta-40 and -42) and tau protein in CSF are measured using a sensitive ELISA-based assay. A quantitative evaluation of mitochondrial DNA copy number, clinical status of the SAH patients and beta amyloid, and tau protein levels will be conducted and reported. RESULTS/ANTICIPATED RESULTS: Preliminary results of four CSF samples showed similar patterns in CSF exosome particle number, particle size and exosomal mtDNA copy number in relation to samples from the admission day. Particle number decreased with time while particle size increased. More patient samples will be analyzed to confirm the patterns. We anticipate that mtDNA copy number will correlate with brain beta-amyloid and tau protein levels. Moreover, we anticipate that the clinical status of the SAH patients will associate with the mtDNA copy number. We specifically predict that higher mtDNA copy number levels will correlate with better clinical outcomes. DISCUSSION/SIGNIFICANCE: Mitochondrial function is critical to brain health, but we lack effective ways to monitor this parameter. Here we focus on a CSF based biomarker, exosome-derived mtDNA, which is intended to reflect the integrity of brain mitochondria. As bioenergetic metabolism influences beta amyloid and tau biology, predicting those levels are important.https://www.cambridge.org/core/product/identifier/S2059866124002978/type/journal_article |
| spellingShingle | Dhanushki Abeykoon Xiaowan Wang Lesya Novikova Amol Ranjan Alexander Gabrielli Russell Swerdlow 331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function Journal of Clinical and Translational Science |
| title | 331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function |
| title_full | 331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function |
| title_fullStr | 331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function |
| title_full_unstemmed | 331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function |
| title_short | 331 Validation of a Novel CSF-Based Biomarker of Mitochondrial Function |
| title_sort | 331 validation of a novel csf based biomarker of mitochondrial function |
| url | https://www.cambridge.org/core/product/identifier/S2059866124002978/type/journal_article |
| work_keys_str_mv | AT dhanushkiabeykoon 331validationofanovelcsfbasedbiomarkerofmitochondrialfunction AT xiaowanwang 331validationofanovelcsfbasedbiomarkerofmitochondrialfunction AT lesyanovikova 331validationofanovelcsfbasedbiomarkerofmitochondrialfunction AT amolranjan 331validationofanovelcsfbasedbiomarkerofmitochondrialfunction AT alexandergabrielli 331validationofanovelcsfbasedbiomarkerofmitochondrialfunction AT russellswerdlow 331validationofanovelcsfbasedbiomarkerofmitochondrialfunction |